These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 8941008

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL, Hurst M.
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [Abstract] [Full Text] [Related]

  • 26. Platinum compounds and paclitaxel in advanced epithelial ovarian cancer.
    Gadducci A, Brunetti I, Cosio S, Giannessi PG, Genazzani AR, Conte P.
    Anticancer Res; 1997; 17(6D):4703-8. PubMed ID: 9494592
    [Abstract] [Full Text] [Related]

  • 27. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.
    Coeffic D, Benhammouda A, Antoine EC, Rixe O, Paraiso D, Auclerc G, Nizri D, Renody N, Grapin JP, Mularoni E, Rattini E, Soubrane C, Weil M, Mortier N, Khayat D.
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):5-8. PubMed ID: 8996589
    [Abstract] [Full Text] [Related]

  • 28. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
    Messori A, Cecchi M, Becagli P, Trippoli S.
    Cancer; 1997 Jun 01; 79(11):2264-6. PubMed ID: 9179077
    [No Abstract] [Full Text] [Related]

  • 29. Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.
    Neymark N, Gorlia T, Adriaenssen I, Baron B, Piccart M.
    Pharmacoeconomics; 2002 Jun 01; 20(7):485-97. PubMed ID: 12093304
    [Abstract] [Full Text] [Related]

  • 30. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
    Hinde S, Epstein D, Cook A, Embleton A, Perren T, Sculpher M.
    Value Health; 2016 Jun 01; 19(4):431-9. PubMed ID: 27325335
    [Abstract] [Full Text] [Related]

  • 31. Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer.
    Poonawalla IB, Lairson DR, Chan W, Piller LB, Du XL.
    Value Health; 2015 Jun 01; 18(4):387-95. PubMed ID: 26091592
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
    Seagle BL, Shahabi S.
    Gynecol Oncol; 2017 Apr 01; 145(1):9-14. PubMed ID: 28196674
    [Abstract] [Full Text] [Related]

  • 34. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer.
    Dranitsaris G, Elia-Pacitti J, Cottrell W.
    Pharmacoeconomics; 2004 Apr 01; 22(6):375-87. PubMed ID: 15099123
    [Abstract] [Full Text] [Related]

  • 35. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
    Alba E, Ciruelos E, López R, López-Vega JM, Lluch A, Martín M, Muñoz M, Sánchez-Rovira P, Seguí MÁ, Liria MR, Pérez-Alcántara F.
    Expert Rev Pharmacoecon Outcomes Res; 2013 Jun 01; 13(3):381-91. PubMed ID: 23534988
    [Abstract] [Full Text] [Related]

  • 36. ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer.
    Foote J, Secord AA, Liang M, Cohn DE, Jewell E, Havrilesky LJ.
    J Oncol Pract; 2017 Dec 01; 13(12):e1030-e1039. PubMed ID: 29016225
    [Abstract] [Full Text] [Related]

  • 37. Cost utility of chemotherapy and best supportive care in non-small cell lung cancer.
    Kennedy W, Reinharz D, Tessier G, Contandriopoulos AP, Trabut I, Champagne F, Ayoub J.
    Pharmacoeconomics; 1995 Oct 01; 8(4):316-23. PubMed ID: 10155673
    [Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness studies in ovarian cancer.
    Szucs TD, Wyss P, Dedes KJ.
    Int J Gynecol Cancer; 2003 Oct 01; 13 Suppl 2():212-9. PubMed ID: 14656283
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.